Synonyms: AS-703026 | AS703026 | MSC1936369B
Compound class:
Synthetic organic
Comment: Pimasertib is an orally bioavailable small-molecule inhibitor of the mitogen-activated protein kinases MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity [4]. It binds to an allosteric site, distinct from the ATP binding site [2] and as such prevents activation rather than inhibiting catalysis.
|
|
No information available. |
Summary of Clinical Use ![]() |
Pimasertic is being assessed in Phase 2 clinical trials for ovarian cancer (in combination with SAR245409, PubChem CID 16123056; NCT01936363) and N-Ras mutated cutaneous melanoma (versus dacarbazine, PubChem CID 5353562; NCT01693068). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types [1]. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation [3]. |